The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: A powerful molecular adjuvant for DNA anti-tumor vaccination. Aug 2010 - :1873-2518 [PMID:20709006] [Ni J] [Schirrmacher V] [Fournier P]
The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting. Apr 2010 - Cancer Immunol. Immunother.; 59(7):1432-0851 [PMID:20130861] [Sui H] [Bai Y] [Wang K] [Li X] [Song C] [Fu F] [Zhang Y] [Li L]
Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. Apr 2010 - :1432-1440 [PMID:20393691] [Song KY] [Wong J] [Gonzalez L] [Sheng G] [Zamarin D] [Fong Y]
Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Jan 2010 - :1476-5594 [PMID:20101224] [Puhlmann J] [Puehler F] [Mumberg D] [Boukamp P] [Beier R]
Oncolytic virus therapy for prostate cancer. Oct 2009 - Int. J. Urol.:1442-2042 [PMID:19832925] [Fukuhara H] [Homma Y] [Todo T]
Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma. Oct 2009 - Mol. Ther.:1525-0024 [PMID:19809404] [Altomonte J] [Marozin S] [Schmid RM] [Ebert O]
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. Jul 2009 - J. Virol.; 83(16):1098-5514 [PMID:19515783] [Jarahian M] [Watzl C] [Fournier P] [Arnold A] [Djandji D] [Zahedi S] [Cerwenka A] [Paschen A] [Schirrmacher V] [Momburg F]
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Jul 2009 - Methods Mol. Biol.; 542:1064-3745 [PMID:19565923] [Schirrmacher V] [Fournier P]
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Jun 2009 - Gene Ther.; 16(6):1476-5462 [PMID:19242529] [Zamarin D] [Vigil A] [Kelly K] [García-Sastre A] [Fong Y]
The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. May 2009 - Cancer Immunol. Immunother.; 58(8):1432-0851 [PMID:19184005] [Seya T] [Matsumoto M]
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Apr 2009 - Mol. Ther.; 17(4):1525-0024 [PMID:19209145] [Zamarin D] [Martínez-Sobrido L] [Kelly K] [Mansour M] [Sheng G] [Vigil A] [García-Sastre A] [Palese P] [Fong Y]
Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice. Mar 2009 - Liver Int.; 29(4):1478-3231 [PMID:19192169] [Li YL] [Wu J] [Wei D] [Zhang DW] [Feng H] [Chen ZN] [Bian H]
Cutting Edge: TLR-Dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells. Mar 2009 - J. Immunol.; 182(7):1550-6606 [PMID:19299691] [Kumagai Y] [Kumar H] [Koyama S] [Kawai T] [Takeuchi O] [Akira S]
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Mar 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287954] [Wilden H] [Fournier P] [Zawatzky R] [Schirrmacher V]
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Mar 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287952] [Pfirschke C] [Schirrmacher V]
